KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 138 filers reported holding KARYOPHARM THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $3,552,741 | +50.0% | 913,301 | +31.1% | 0.02% | +20.0% |
Q4 2022 | $2,368,664 | -35.1% | 696,666 | +4.3% | 0.02% | -48.7% |
Q3 2022 | $3,647,000 | +76.0% | 668,004 | +45.4% | 0.04% | +105.3% |
Q2 2022 | $2,072,000 | -65.2% | 459,409 | -43.2% | 0.02% | -45.7% |
Q1 2022 | $5,962,000 | +143.6% | 808,939 | +112.6% | 0.04% | +169.2% |
Q4 2021 | $2,447,000 | +13.3% | 380,568 | +2.6% | 0.01% | -13.3% |
Q3 2021 | $2,159,000 | -17.2% | 370,983 | +46.8% | 0.02% | -6.2% |
Q2 2021 | $2,609,000 | -8.4% | 252,764 | -6.6% | 0.02% | -15.8% |
Q1 2021 | $2,847,000 | +212.2% | 270,663 | +359.3% | 0.02% | +111.1% |
Q4 2020 | $912,000 | -55.3% | 58,933 | -57.8% | 0.01% | -64.0% |
Q3 2020 | $2,040,000 | +88.4% | 139,729 | +144.4% | 0.02% | +66.7% |
Q2 2020 | $1,083,000 | +353.1% | 57,177 | +360.2% | 0.02% | +50.0% |
Q1 2020 | $239,000 | -88.2% | 12,425 | -88.2% | 0.01% | -67.7% |
Q4 2019 | $2,025,000 | +7.1% | 105,657 | -46.3% | 0.03% | +3.3% |
Q3 2019 | $1,891,000 | – | 196,611 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
COMMODORE CAPITAL LP | 3,561,052 | $26,245,000 | 5.86% |
Palo Alto Investors LP | 5,621,533 | $41,431,000 | 3.20% |
Iron Triangle Partners LP | 2,000,000 | $14,740,000 | 1.75% |
Altium Capital Management LP | 645,000 | $4,754,000 | 1.59% |
Birchview Capital, LP | 269,332 | $1,985,000 | 1.43% |
Rubric Capital Management LP | 3,607,443 | $26,587,000 | 0.96% |
Lombard Odier Asset Management (Switzerland) SA | 776,053 | $5,720,000 | 0.45% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,344,929 | $9,912,000 | 0.40% |
Golden State Equity Partners | 41,850 | $308,000 | 0.16% |
Hennion & Walsh Asset Management, Inc. | 385,837 | $2,844,000 | 0.15% |